NASDAQ: OTLK
Outlook Therapeutics Inc Stock Ownership - Who owns Outlook Therapeutics?

Insider buying vs selling

Have Outlook Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ghiath M. SukhtianDirector2025-05-274,285,714$1.40
$6.00MBuy
Ghiath M. SukhtianDirector2025-01-173,458,571$2.51
$8.68MBuy
Lawrence A. KenyonChief Financial Officer2024-09-265,000$5.69
$28.45kBuy

1 of 1

OTLK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OTLK insiders and whales buy or sell their stock.

OTLK Shareholders

What type of owners hold Outlook Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ghiath M. Sukhtian249.05%83,599,563$148.81MInsider
Faisal Ghiath Sukhtian166.48%55,884,786$99.47MInsider
Biolexis Pte Ltd75.80%25,443,159$45.29MInsider
Arun Kumar Pillai68.47%22,982,529$40.91MInsider
Pankaj Mohan24.68%8,285,115$14.75MInsider
Syntone Ventures LLC5.08%1,705,438$3.04MInsider
Schonfeld Strategic Advisors LLC4.63%1,552,744$2.76MInstitution
Blackrock Inc3.70%1,242,372$2.21MInstitution
Sphera Funds Management Ltd2.55%857,142$1.53MInstitution
Vanguard Group Inc2.49%837,407$1.49MInstitution

1 of 3

OTLK vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OTLK3.41%96.59%Net BuyingNet Buying
IRD4.48%95.52%Net Buying
SER0.84%99.16%Net BuyingNet Buying
INMB25.54%31.87%Net Buying
PDSB18.00%25.86%Net Buying

Outlook Therapeutics Stock Ownership FAQ

Who owns Outlook Therapeutics?

Outlook Therapeutics (NASDAQ: OTLK) is owned by 21.11% institutional shareholders, 598.25% Outlook Therapeutics insiders, and 0.00% retail investors. Ghiath M. Sukhtian is the largest individual Outlook Therapeutics shareholder, owning 83.60M shares representing 249.05% of the company. Ghiath M. Sukhtian's Outlook Therapeutics shares are currently valued at $148.81M.

If you're new to stock investing, here's how to buy Outlook Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.